Spots Global Cancer Trial Database for hormone receptor positive
Every month we try and update this database with for hormone receptor positive cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer | NCT00549822 | Breast Cancer | Letrozole | 18 Years - | Massachusetts General Hospital | |
| Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients | NCT02511639 | Breast Cancer M... | Everolimus Aromatase Inhib... | 18 Years - | Istituto Oncologico Veneto IRCCS | |
| Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | NCT05191004 | Advanced Breast... Metastatic Brea... Breast Cancer Breast Carcinom... Cancer of the B... Cancer of Breas... Malignant Tumor... Breast Tumor | NUV-422 Fulvestrant | 18 Years - | Nuvation Bio Inc. | |
| Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer | NCT02690480 | Breast Neoplasm... | PD-0332991 (Pal... Fulvestrant Placebo | 18 Years - | Spanish Breast Cancer Research Group | |
| IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma | NCT02614833 | Adenocarcinoma ... | IMP321 (eftilag... Placebo Paclitaxel | 18 Years - | Immutep S.A.S. | |
| PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY | NCT03423199 | Breast Neoplasm... | Palbociclib Placebo Tamoxifen Goserelin | 18 Years - | National Cancer Center, Japan | |
| Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy | NCT03220178 | Breast Neoplasm | Palbociclib Fulvestrant Anastrozole Letrozole Exemestane | 18 Years - | Palleos Healthcare GmbH | |
| Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer | NCT05736367 | Breast Cancer | U-13C-glucose | 18 Years - | Rutgers, The State University of New Jersey | |
| A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer | NCT05504213 | Breast Cancer | HS-10352 combin... HS-10352 combin... | 18 Years - | Jiangsu Hansoh Pharmaceutical Co., Ltd. | |
| Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy | NCT04318223 | Metastatic Brea... Locally Advance... | Palbociclib | 18 Years - 64 Years | Consorzio Oncotech | |
| Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients | NCT01446185 | Breast Cancer | Oncotype DX bre... | 18 Years - | Genomic Health®, Inc. | |
| MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer | NCT05108740 | Advanced Hormon... | everolimus | 18 Years - 99 Years | Novartis | |
| Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD | NCT01655004 | Breast Carcinom... | Exemestane | 21 Years - 99 Years | National University Hospital, Singapore | |
| Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD | NCT01655004 | Breast Carcinom... | Exemestane | 21 Years - 99 Years | National University Hospital, Singapore | |
| Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib | NCT05252988 | Early-stage Bre... HER2 Positive B... Hormone Recepto... | Neratinib Loperamide Colesevelam | 18 Years - | Spanish Breast Cancer Research Group | |
| Pilot for The Breast Cancer Endocrine Therapy Adherence (BETA) Trial | NCT02256670 | Breast Cancer | Text Message Ap... | 18 Years - | Yale University | |
| Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer | NCT04337658 | HER2-positive B... | Pertuzumab Trastuzumab Fulvestrant Capecitabine | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD | NCT01655004 | Breast Carcinom... | Exemestane | 21 Years - 99 Years | National University Hospital, Singapore | |
| Managed Access Program to Provide Access to Alpelisib for Patients With Advanced Breast Cancer | NCT04473040 | HR+, HER2-, Adv... | alpelisib | 18 Years - 99 Years | Novartis | |
| A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | NCT01160211 | Neoplasms, Brea... | lapatinib trastuzumab Aromatase inhib... lapatinib | 18 Years - | Novartis | |
| QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer | NCT00626106 | Breast Cancer Breast Tumors Metastatic Canc... | AMG 479 or plac... AMG 479 or plac... AMG 479 or plac... | 18 Years - | NantCell, Inc. | |
| Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane | NCT02109913 | Hormone Recepto... Metastatic Brea... | Everolimus plus... | 18 Years - | Amsterdam UMC, location VUmc | |
| Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer | NCT00171808 | Endometrial Can... | Letrozole | 18 Years - | Novartis | |
| Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer | NCT00549822 | Breast Cancer | Letrozole | 18 Years - | Massachusetts General Hospital | |
| IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma | NCT02614833 | Adenocarcinoma ... | IMP321 (eftilag... Placebo Paclitaxel | 18 Years - | Immutep S.A.S. | |
| Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting | NCT00618657 | Breast Cancer HER2-negative B... HER2-positive B... Recurrent Breas... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | Carboplatin paclitaxel albu... bevacizumab trastuzumab magnetic resona... therapeutic con... | 21 Years - 90 Years | University of California, Irvine | |
| Pilot for The Breast Cancer Endocrine Therapy Adherence (BETA) Trial | NCT02256670 | Breast Cancer | Text Message Ap... | 18 Years - | Yale University | |
| A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer | NCT02333370 | Hormone Recepto... | LEE011 Letrozole Tamoxifen Fulvestrant goserelin | 18 Years - | Novartis | |
| Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane | NCT02109913 | Hormone Recepto... Metastatic Brea... | Everolimus plus... | 18 Years - | Amsterdam UMC, location VUmc | |
| Local Therapy for ER/PR-positive Oligometastatic Breast Cancer | NCT04698252 | Breast Cancer | Radiotherapy Surgery Radiofrequency ... | 18 Years - | Instituto do Cancer do Estado de São Paulo | |
| Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | NCT05191004 | Advanced Breast... Metastatic Brea... Breast Cancer Breast Carcinom... Cancer of the B... Cancer of Breas... Malignant Tumor... Breast Tumor | NUV-422 Fulvestrant | 18 Years - | Nuvation Bio Inc. | |
| Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy | NCT00759642 | Metastatic Brea... | lapatinib | 18 Years - | University of Kansas Medical Center | |
| Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. | NCT00921115 | Invasive Breast... | Fulvestrant Anastrazole | 18 Years - | University of Kansas Medical Center | |
| Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients | NCT02511639 | Breast Cancer M... | Everolimus Aromatase Inhib... | 18 Years - | Istituto Oncologico Veneto IRCCS | |
| MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer | NCT05108740 | Advanced Hormon... | everolimus | 18 Years - 99 Years | Novartis | |
| Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women | NCT01266213 | Metastatic Brea... Estrogen Recept... Breast Cancer N... | Fulvestrant plu... Anastrozole plu... Goserelin | - 55 Years | Samsung Medical Center | |
| Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) | NCT00310180 | Breast Adenocar... Hormone Recepto... Stage IA Breast... Stage IB Breast... Stage IIA Breas... Stage IIB Breas... Stage IIIB Brea... | Anastrozole Exemestane Laboratory Biom... Letrozole Quality-of-Life... Radiation Thera... Tamoxifen Citra... | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| High Dose Vitamin D vs Standard Dose Vitamin D Study | NCT01988090 | Breast Cancer | 800 IU Vitamin ... 50,000 IU Vitam... | 18 Years - | Baylor Breast Care Center | |
| A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer | NCT02333370 | Hormone Recepto... | LEE011 Letrozole Tamoxifen Fulvestrant goserelin | 18 Years - | Novartis | |
| A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) | NCT05104866 | Breast Cancer | Dato-DXd Capecitabine Gemcitabine Eribulin Vinorelbine | 18 Years - | AstraZeneca | |
| Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor | NCT01610284 | Breast Cancer | Fulvestrant BKM120 BKM120 matching... | 18 Years - | Novartis | |
| Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy | NCT00759642 | Metastatic Brea... | lapatinib | 18 Years - | University of Kansas Medical Center | |
| Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) | NCT00310180 | Breast Adenocar... Hormone Recepto... Stage IA Breast... Stage IB Breast... Stage IIA Breas... Stage IIB Breas... Stage IIIB Brea... | Anastrozole Exemestane Laboratory Biom... Letrozole Quality-of-Life... Radiation Thera... Tamoxifen Citra... | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer | NCT05504213 | Breast Cancer | HS-10352 combin... HS-10352 combin... | 18 Years - | Jiangsu Hansoh Pharmaceutical Co., Ltd. | |
| TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer | NCT02586675 | Breast Cancer Breast Cancer -... Breast Cancer -... | Tamoxifen Ribociclib Goserelin | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer | NCT02586675 | Breast Cancer Breast Cancer -... Breast Cancer -... | Tamoxifen Ribociclib Goserelin | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer | NCT00549822 | Breast Cancer | Letrozole | 18 Years - | Massachusetts General Hospital | |
| Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer | NCT02690480 | Breast Neoplasm... | PD-0332991 (Pal... Fulvestrant Placebo | 18 Years - | Spanish Breast Cancer Research Group | |
| TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer | NCT02586675 | Breast Cancer Breast Cancer -... Breast Cancer -... | Tamoxifen Ribociclib Goserelin | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer | NCT02333370 | Hormone Recepto... | LEE011 Letrozole Tamoxifen Fulvestrant goserelin | 18 Years - | Novartis | |
| Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients | NCT02511639 | Breast Cancer M... | Everolimus Aromatase Inhib... | 18 Years - | Istituto Oncologico Veneto IRCCS | |
| A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery | NCT05549505 | Breast Cancer | ARV-471 Anastrozole Surgical resect... | 18 Years - | Arvinas Inc. | |
| Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer | NCT02690480 | Breast Neoplasm... | PD-0332991 (Pal... Fulvestrant Placebo | 18 Years - | Spanish Breast Cancer Research Group | |
| QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer | NCT00626106 | Breast Cancer Breast Tumors Metastatic Canc... | AMG 479 or plac... AMG 479 or plac... AMG 479 or plac... | 18 Years - | NantCell, Inc. | |
| Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting | NCT00618657 | Breast Cancer HER2-negative B... HER2-positive B... Recurrent Breas... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | Carboplatin paclitaxel albu... bevacizumab trastuzumab magnetic resona... therapeutic con... | 21 Years - 90 Years | University of California, Irvine | |
| Managed Access Program to Provide Access to Alpelisib for Patients With Advanced Breast Cancer | NCT04473040 | HR+, HER2-, Adv... | alpelisib | 18 Years - 99 Years | Novartis | |
| Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer | NCT05736367 | Breast Cancer | U-13C-glucose | 18 Years - | Rutgers, The State University of New Jersey |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
